Member Info for mulledwine

Dr. Katya Tsaioun, Cyprotex's Chief Scientific Officer, comments on the launch of this improved assay: "Drug, cosmetic and agrichemical compounds still fail in late-stage development due to genotoxicity, at a tremendous cost to the industries. Consequently, as companies try to increase success rates in later stages of development, in vitro micronucleus testing, alongside other toxicity assays, is increasingly becoming a routine early-stage assay." Dr. Anthony Baxter, Cyprotex's CEO, announces: "Cyprotex is pleased to support pharmaceutical, cosmetic and agrichemical companies with this improved method for identifying genotoxicity during early-stage development as part of a comprehensive de-risking strategy."

Cyprotex Adds High Content Screening In Vitro Micronucleus Test High Content Screening Approach Improves Early Genotoxicity Detection Cyprotex PLC(LSE:CRX), the preclinical ADME Tox services company, today announces that it has added to its service portfolio an automated, high content screening (HCS) implementation of the in vitro micronucleus test for detection of genotoxicity. This approach improves the accuracy and cost-effectiveness of early-stage genotoxicity testing over existing assay methods. The micronucleus test identifies genotoxic carcinogens, i.e., carcinogens that act by causing damage to DNA. During cell division, if a chromosome or a fragment of a chromosome fails to be incorporated into one of the daughter nuclei - typically as a consequence of genetic damage - the chromosome may form its own micronucleus. This micronucleus can be detected using HCS techniques. Using HCS to detect these micronuclei has several advantages over traditional manual methods, the most important of which is that it improves accuracy and reliability because it allows automated scoring and an increase in statistical power through HCS's ability to rapidly and automatically measure effects on large numbers of cells. The automation also allows large volumes of compounds to be screened faster, to accommodate early discovery needs. Over the last decade the Organization for Economic Cooperation and Development (OECD) has established guidelines for the micronucleus test. Validation by European Center for the validation of Alternative Methods (ECVAM), an organisation that promotes the scientific and regulatory acceptance of non-animal tests of importance to biomedical sciences, led to the in vitro micronucleus test being accepted as a scientifically valid alternative to the in vitro chromosome aberration assay for genotoxicity testing. Cyprotex's fully automated assay design has been developed following these guidelines.

http://www.investegate.co.uk/Article.aspx?id=201109270700289631O

http://www.investegate.co.uk/Article.aspx?id=201109260700168683O

Goldenport launches £1m share buy back Date: Monday 26 Sep 2011 LONDON (ShareCast) - International shipping firm Goldenport Holdings is to buy back up to £1m in its own shares, saying the shares were trading at a significant discount to the underlying value of the company. The buy-back programme will be conducted in accordance with a resolution passed at the firm's last AGM, which gave directors permission to buy stock representing around 10% of the company's issued share capital. The company added it was not planning to purchase more than 50% of the average daily volume traded in the twenty trading days preceding the date of purchase. Any shares purchased would be held in treasury, it said. Captain Paris Dragnis, Goldenport's founder and chief executive, said recent share price performance neither reflected the underlying value of the company's assets nor the firm's belief in its medium to longer term prospects. "Positive developments such as the improved profitability evidenced in our recent interim results, our increased dividend payout, our enlarged operational fleet following the completion of our initial new building programme and our strong balance sheet, seem to be disconnected from the current share price," he said. "Therefore we believe that the limited buy-back of our shares is in the best interests of the company and its shareholders."

Charles Stanley downgrades Hellenic Carriers from buy to hold, target price cut from 129p to 50p.

Brendan Dow, Managing Director of Ceramic Fuel Cells said "We are very pleased to have received this large order from Zestiq, which complements the recent order for 100 units from our German distributor sanevo. We look forward to Zestiq and their utility partners installing these BlueGen generators with early customers and then driving further BlueGen sales in The Netherlands market."

Ceramic Fuel Cells (CFU) the developer of high efficiency and low emission power products, announced it has received an order for 100 BlueGen gas-to-electricity generators from its Dutch distributor. The group appointed Zestiq as its partner for distribution in the Netherlands in July, targeting small commercial and residential customers. The order complements a recent order for 100 units from its German distributor, Sanevo. Ceramic shares rose 0.375p to 8.125p.

Commenting on the results, John Duffy, Chief Executive of Finsbury Food Group plc, said: ""We are pleased to have returned to organic growth, an important milestone for the group. We are emerging from a complex and exhaustive programme of reorganisation and despite the macro economic factors continuing to buffet the business and our customers, our structured approach has clearly started to bear fruit. The difficulties we face should not be underestimated, the global commodities bubble has exerted unprecedented pressure on margins. Prices for butter, sugar and wheat have soared over the last 18 months. Keeping things affordable for customers is essential. "I am delighted that we have succeeded in steering the Group through another demanding year. The reality is that testing times still lie in wait. However, our distinctive range of products, commitment to value and robust performance in a testing climate bode well for the challenge ahead."

Highlights § Group revenue up 12.6% to £189.6 million (2010: £168.3m) § Adjusted* profit before tax up 8.3% to £5.8 million (2010: £5.4m) § Cake division returns to growth with sales increasing by 12.1% to £139.6 million (2010: £124.6m) § Bread & Free From sales growth of 14.2% to £50.0 million (2010: £43.7m) from investment behind Vogels and ongoing growth in the fresh Free From product range with Genius and own label § Adjusted* diluted earnings per share 7.1p (2010: 7.0p) § Total net bank debt reduced by 10.4% to £32.7 million at the year end (2010: £36.5m) § Banking facilities with HSBC extended to 2017 § Discounted deferred consideration reduced by 28.3% to £4.3 million at year end (2010: £6.0m) § Strong organic growth across all divisions, despite the exceptional impact of commodity and cost inflation Operational Highlights: § Licensed brand growth across all divisions § Working with Genius Foods Limited to expand the Free From product portfolio § Re-launch of Vogel's speciality bread brand § Adding Disney small cakes to our licensed portfolio

http://www.investegate.co.uk/Article.aspx?id=201109260700148609O

Finsbury Food Group (FIF) shares gained 1.25p to 25.75p as the company announced a 12.6% increase in revenue to 189.6 million pounds for the year ended 2nd June 2011. The group's main line of business, cake production, saw a return to growth as sales increased 12.1% to 139.6 million, while Bread and Free From sales rose 14.2% to 50 million pounds. Pre-tax profits rose just 23% to 5.99 million pounds as exceptionally high cost inflation impacted margins.

Those were decent figures today

Henrik Bang, CEO of Netcall, commented, "This has been a period of substantial progress for Netcall, during which we have significantly increased our organisational capability and customer base, and broadened our product suite through the successful acquisition and integration of Telephonetics. We are pleased with the increase in new customer business and the initial cross-sales. As a result of our increased profit levels and cash generation we are delighted to propose the payment of a maiden dividend. "The new year has started well with sales orders ahead of the same period last year. Whilst the Board remains mindful of the economic climate, our developing pipeline together with the full year impact of our cost savings programme, give the Board confidence in achieving a successful outcome for the year ahead."

http://www.investegate.co.uk/Article.aspx?id=201109260700188757O

Pre-tax profits rose to 546,000 pounds in the six months to June, up from a loss of 235,000 pounds, at Netcall (NET), following the successful acquisition of Telephonetics. Revenue at the customer services provider rose 229% to 13.62 million pounds, with 68% of this corresponding to recurring sales. The acquisition has provided Netcall with increased organisational capability, a larger customer base and the opportunity to cross-sell products. Netcall also announced a maiden dividend of 0.4p per share. The shares jumped 1.125p to 17.375p

Graham Storey, CEO of Transense commented: "We are delighted to be able announce GM as the partner Transense have been working with on the Flexplate project since 2004. Gaining such a strong endorsement of our SAW sensor technology from an engineering team as highly regarded as GM's, reaffirms our belief in the commercial potential of our core technology and supporting patent portfolio. The complexity, level of testing required and technical challenges we have overcome in bringing such a significant new technology to this stage of development cannot be underestimated, and it is testament to both GM's and Transense's technical teams that the project has progressed comparatively quickly."

http://www.investegate.co.uk/Article.aspx?id=201109260700198790O

Transense Technologies (TRT) announced that subsequent to recent commercial developments, General Motors has been identified as the end user of the group's Surface Acoustic Wave technology, to be used as part of a torque 'flexplate' sensor. The flexplate is an integral part of the vehicle power chain control system and has the potential to improve vehicle driveability. General Motors is to evaluate the technology for real-time vehicle control. Transense share remained unchanged at 3.375p

Michael Marx, Chairman, commented, "We are now in the second year of our three year growth plan and, as the Group's results for the first half of the year indicate, progress towards its objectives has been good. Underlying profit before tax has risen by 16% to £3.5m for the six months to 30 June 2011, with revenues increasing by 6% to £92.3 million over the same period. The results show the continuing steady progress we are making to develop our core insurance market and, while sensibly leveraging our infrastructure and systems to build sales in non-insurance funded markets, especially fleet and retail, where our presence is relatively low currently. While we expect current economic conditions to create some challenges, we believe that the Group is well positioned for the remainder of the year and remain very positive about the Group's long term prospects."